Bellevue Group Ag United Therapeutics Corp Transaction History

Bellevue Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$205.95 - $280.43 $18,329 - $24,958	-89 Reduced 29.57%	212 $58,000
Q3 2022 Nov 14, 2022	BUY	$203.3 - $244.17 $21,956 - $26,370	108 Added 55.96%	301 $63,000
Q2 2022 Aug 11, 2022	BUY	$174.81 - $241.14 $33,738 - $46,540	193 New	193 $45,000
Q1 2018 May 09, 2018	SELL	$107.21 - $151.94 $1.84 Million - $2.61 Million	-17,200 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$118.58 - $151.28 $521,752 - $665,632	-4,400 Reduced 20.37%	17,200 $2.55 Million
Q3 2017 Nov 13, 2017	BUY	$114.6 - $136.81 $1.58 Million - $1.89 Million	13,800 Added 176.92%	21,600 $2.53 Million
Q2 2017 Aug 14, 2017	BUY	N/A	7,800	7,800 $1.01 Million

723

60.9M

123K

104K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.3B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.